SCHEMBL4924906

SCHEMBL4924906

COc1ccc(-n2c(=S)[nH]c3ncccc32)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.69
ALDH1A1 P00352 4/20 0.62
HPGD P15428 3/20 0.62
MAPT P10636 2/20 0.62
SMN1; SMN2 Q16637 1/20 0.62
ADORA3 P0DMS8 1/20 0.51
ADORA1 P30542 1/20 0.51
KMT2A Q03164 3/20 0.49
MEN1 O00255 1/20 0.49
ATM Q13315 1/20 0.49
KDM4E B2RXH2 2/20 0.47
GAA P10253 2/20 0.47
CYP3A4 P08684 1/20 0.47
RECQL P46063 1/20 0.47
LOXL3 P58215 1/20 0.46
LOXL2 Q9Y4K0 1/20 0.46
CCNB2 O95067 1/20 0.44
CDK1 P06493 1/20 0.44
CCNB1 P14635 1/20 0.44
RIPK1 Q13546 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4931641 0.79 ALDH1A1 (0.63) PKMALDH1A1HPGDMAPTSMN1; SMN2
SCHEMBL4933113 0.75 ALDH1A1 (0.66) PKMALDH1A1HPGDMAPTSMN1; SMN2
SCHEMBL23233130 0.74 LOXL3 (0.42) PKMALDH1A1MAPTADORA3LOXL3
SCHEMBL14096393 0.74 PKM (0.67) PKMALDH1A1HPGDMAPTSMN1; SMN2
SCHEMBL19463071 0.74 LOXL3 (0.43) PKMALDH1A1MAPTSMN1; SMN2KMT2A
SCHEMBL29463940 0.74 LOXL3 (0.43) PKMALDH1A1MAPTSMN1; SMN2KMT2A
SCHEMBL4932698 0.71 HPGD (0.73) PKMALDH1A1HPGDMAPTSMN1; SMN2
SCHEMBL15643529 0.71 PSMB8 (0.52) PKMALDH1A1MAPTSMN1; SMN2KDM4E
SCHEMBL6241021 0.68 HPGD (0.56) PKMALDH1A1HPGDMAPTSMN1; SMN2
SCHEMBL4934253 0.68 HPGD (0.63) PKMALDH1A1HPGDMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080021069-A1 Receptor Function Regulating Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-24 US disclosed
US-20080021069-A1 Receptor Function Regulating Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-24 US disclosed
US-20080021069-A1 Receptor Function Regulating Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-24 US disclosed
EP-1810677-A1 RECEPTOR FUNCTION REGULATING AGENT Takeda Pharmaceutical Company Limited (JP) 2007-07-25 EP disclosed
EP-1810677-A1 RECEPTOR FUNCTION REGULATING AGENT Takeda Pharmaceutical Company Limited (JP) 2007-07-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021069-A1 Receptor Function Regulating Agent GPR119, INSR, GPR65 PKM 3646/4885ALDH1A1 1870/4885HPGD 1922/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.